DBS Maintains West Pharmaceutical Services(WST.US) With Buy Rating
DBS Maintains West Pharmaceutical Services(WST.US) With Buy Rating
Analysts Offer Insights on Healthcare Companies: West Pharmaceutical Services (WST) and HCA Healthcare (HCA)
Jefferies Adjusts Price Target on West Pharmaceutical Services to $345 From $426
Jefferies Maintains West Pharmaceutical Services(WST.US) With Buy Rating, Cuts Target Price to $345
Stephens Adjusts Price Target on West Pharmaceutical Services to $340 From $400
Hold Rating on West Pharmaceutical Services Amid Forecast Challenges and Demand Slowdown
Stephens Adjusts Price Target on West Pharmaceutical Services to $400 From $420
Jefferies Adjusts Price Target on West Pharmaceutical Services to $426 From $423
West Pharmaceutical Services: Strong Q1 Performance and Upbeat FY24 Outlook Bolster Buy Rating
Buy Rating Affirmed for West Pharmaceutical Services on Robust Market Position and Growth Prospects
West Pharmaceutical Servs Analyst Ratings
Deutsche Bank Raises West Pharmaceutical Services Price Target to $355 From $350, Maintains Hold Rating
Analysts Have Conflicting Sentiments on These Healthcare Companies: Bio-Rad Laboratories (BIO), Ultragenyx Pharmaceutical (RARE) and West Pharmaceutical Services (WST)
Keybanc Maintains Overweight on West Pharmaceutical Servs, Raises Price Target to $470
West Pharmaceutical Servs Analyst Ratings
Jefferies Upgrades West Pharmaceutical Services to Buy From Hold, Adjusts Price Target to $536 From $323
West Pharmaceutical Servs Analyst Ratings
Hold Rating on West Pharmaceutical Services Amid Balanced Growth Prospects and Expansion Investments
Stephens & Co. Maintains Overweight on West Pharmaceutical Servs, Lowers Price Target to $390